LUNA INNOVATIONS INCORPORATED — Department of Defense SBIR Phase II: The proposed Phase II program is designed to build upon the successes of the Phase I feasi

Description

The proposed Phase II program is designed to build upon the successes of the Phase I feasibility study and develop an advanced blood simulant for training of combat first responders in the use of modern hemostatic products. The blood simulant will exhibit a caking/clotting response in the presence of simulated hemostatic agents while accurately approximating the viscosity and color of human blood. The two primary goals of the Phase II program are to (1) optimize and scale up production of blood simulant solutions and simulated hemostatic dressings and (2) incorporate them into existing hemorrhage simulation platforms and demonstrate them to the simulation, training and readiness (STR) community. The resulting simulated blood product will be inexpensive, biologically safe, easy to use and easily integrated into current and future training regimes and simulators. It will be safe for use with human subjects, easily cleansed from skin and clothing and will not require special storage conditions. Combination of the blood simulant with simulated hemostatic dressings into a hemostatic products training kit will enhance convenience and accelerate market acceptance.